Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amara drops versus placebo for irritable bowel syndrome
2026-526668-19-00Phase 4Authorised
- Sponsor
- Weleda
- Start
- Aug 2026
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Amara-Tropfen with Placebo (2 arms). Primary endpoint: Change in gastrointestinal discomfort intensity. Planned start Aug 2026; status: authorised.
02
Drugs
Amara-Tropfen
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2026-526668-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526668-19-00.